Aptabridge Therapeutics is creating a next generation drug design platform to leverage DNA nanoparticles for immunotherapy. We develop highly stable, bi and multi specific molecules with the aim to treat multifaceted, complex diseases by engaging two disease targets with one molecule.
By employing DNA nanoparticles instead of antibodies for immunotherapy, we will overcome challenges faced by bispecific antibodies with a product that promises to be safer, lower cost, and easier to manufacture. We are also employing a modular design strategy that allows us to reliably mix and match binding modules on our nanoparticles. This allows us to take working immune targeting modules and swap out different disease targeting modules to treat a wide range of diseases, making this platform highly versatile and scalable.